Aadel Chaudhuri

Aadel Chaudhuri, MD, PhD

Specializes In
  • Cancer (Oncology)
  • Radiation Oncology
Languages Spoken
  • English


Sees Patients For

Thoracic oncology, head and neck oncology, gastrointestinal oncology, stereotactic body radiotherapy



Academic Title(s)

Assistant Professor, Radiation Oncology

Research Interests

Dr. Chaudhuri’s research focuses on cell-free nucleic acids, and specifically on the identification and measurement of circulating tumor DNA (ctDNA) as a cancer biomarker. In a paper published in Cancer Discovery in 2017, he and his colleagues showed that they could measure ctDNA in the blood of non-metastatic lung cancer patients shortly after completing treatment and months before standard-of-care CT imaging. Post-treatment ctDNA detection served as a biomarker for ultimate disease relapse and survival, and genomic analyses of the ctDNA identified candidacy for precision medicine drugs including tyrosine kinase inhibitors and immune checkpoint inhibitors. Dr. Chaudhuri is interested in applying these findings to clinical practice, exploring ctDNA as a biomarker in other malignancies, and using ctDNA as a tool to monitor responses to radiotherapy and immunotherapy.

Publications & Research

View research profile »


Post-doctoral research, Applied Genomics &Precision Medicine

2018 Stanford University, Stanford, California

Chief Resident, Radiation Oncology

2018 Stanford Cancer Institute, Stanford, California

Medical Degree

2013 Stanford University, Stanford, California

PhD, Biology

2011 California Institute of Technology, Pasadena, California

Financial Disclosures
  • Droplet Biosciences
    • Equity: Yes
    • Reporting Date: 05/01/2023
  • LiquidCell DX
    • Equity: Yes
    • Reporting Date: 05/01/2023

Washington University and its physicians and health professionals are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians and health professionals work collaboratively with pharmaceutical, medical device or other medical care related companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our physicians and health professionals have an ownership or potential ownership interest in a commercial company; and/or are paid by a commercial company to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians or health professionals must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this website, physicians and health professionals earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.